📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Jagsonpal Pharma Q3 PAT Rises 10% to ₹12.5 Cr; Management Guides for Q4 Recovery
Jagsonpal Pharmaceuticals reported a flattish Q3 FY26 with revenue at ₹73 crores, though PAT grew 10% YoY to ₹12.5 crores. The company faced headwinds as its relevant market (RPM) grew only 3-3.5% compared to the broader pharma market's 8% growth. Management attributed the performance to internal recalibrations and leadership transitions, including a ₹2.1 crore one-time provision for the new labor code. Despite the slow quarter, the company maintains a strong cash position of ₹176 crores and expects double-digit growth to resume from Q4 FY26.
Key Highlights
Q3 FY26 Revenue stood at ₹73 crores, while 9M FY26 revenue grew 6% YoY to ₹223 crores.
PAT for the quarter increased by 10% YoY to ₹12.5 crores with margins improving 180 bps to 17.1%.
Free cash balance reached ₹176 crores, reflecting an increase of ₹15.2 crores during the quarter.
Exceptional item of ₹2.1 crores provided for past service costs related to the new labor code.
Management expects growth acceleration to double digits starting from Q4 FY26 following field force recalibration.
💼 Action for Investors
Investors should monitor the promised recovery in Q4 to see if internal leadership changes and strategy refreshes translate into higher volume growth. The strong cash position and debt-free status provide a significant cushion for future expansion or acquisitions.